Business Context and Reporting Period
This Form 8-K was filed by Rocky Mountain Chocolate Factory, Inc. on March 24, 2017. The report addresses a corporate governance issue regarding the composition of the Company's Audit Committee following the death of a board member.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on regulatory compliance status rather than financial performance.
Material Changes
The Company received a notice from the Nasdaq Stock Market, Inc. stating it is no longer in compliance with Listing Rule 5605(c)(2)(A). This rule requires the Audit Committee to be composed of at least three independent directors. The non-compliance resulted from the passing of Mr. Gerald A. Kien, a member of the Board and Audit Committee, on February 22, 2017, which left the committee with only two independent directors.
Outlook, Risks, and Management Commentary
- Cure Period: Under Listing Rule 5605(c)(4), the Company has a cure period to regain compliance. This period expires on the earlier of the date of the next annual shareholders' meeting or August 21, 2017.
- Management Action: The Board is actively working to fill the vacancy left by Mr. Kien.
- Expectation: The Company expects to be compliant with the audit committee composition requirements by or before the end of the cure period.
Investor Verification Checklist
- Confirm the date of the Company's next annual shareholders' meeting to determine the exact expiration of the cure period.
- Monitor subsequent filings for the appointment of a new independent director to the Audit Committee.
- Verify that the Company has not received further correspondence from Nasdaq regarding potential delisting.